Lonza has launched its new Developability Assessment Platform designed to reduce attrition rates and improve the ranking of early drug candidates. The prediction tools include a suite of in silico services that assess candidates for fitness for large-scale manufacture, and immunogenicity profiles in humans in both discovery and early stage biologic drug development.   The Manufacturability Assessment Service analyzes chemical degradation pathways and post-translational modifications including de...